Valuation : Tectonic Therapeutic, Inc.

Market Cap 601M 517M 486M 444M 830M 56.85B 833M 5.77B 2.23B 29.11B 2.26B 2.21B 92.74B P/E 2026 *
-6.04x
P/E 2027 * -5.68x
Enterprise Value 127M 109M 103M 93.73M 175M 12.01B 176M 1.22B 471M 6.15B 477M 466M 19.58B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
62.15%
Yield 2026 *
-
Yield 2027 * -
1 day+2.77%
1 week+2.71%
Current month+2.71%
1 month-0.74%
3 months+6.03%
6 months-14.27%
Current year+47.41%
1 week 29.45
Extreme 29.45
32.52
1 month 28.96
Extreme 28.96
38.85
Current year 16.77
Extreme 16.77
39.53
1 year 14.38
Extreme 14.385
39.53
3 years 13.7
Extreme 13.7
61.07
5 years 13.7
Extreme 13.7
61.07
10 years 13.7
Extreme 13.7
61.07
Date Insider Type Main position Quantity % Market Cap. Importance
8/25/26 Exercice

Chief Technology Officer

129 0.0007%
8/12/26 Exercice

Chief Technology Officer

129 0.0007%
6/30/26 Exercice

Chief Technology Officer

516 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
+2.77%+2.71%+83.04% - 601M
-0.38%-0.99%+42.69%+100.85% 67.82B
-2.71%-0.71%+35.89%+81.43% 63.22B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
+0.74%-1.25%+25.35%+14.43% 25.38B
-1.11%+0.90%+22.24%-18.50% 19.89B
+1.15%-5.02%+219.82%+379.02% 17.4B
-1.10%-0.98%-7.88%+521.00% 14.95B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.03%+0.14%+45.62%+178.65% 27.75B
Weighted average by Cap. -0.66%+0.87%+36.98%+140.19%

Financials

2026 *2027 *
Net sales - -
Net income -101M -87.04M -81.86M -74.73M -140M -9.57B -140M -971M -375M -4.9B -380M -372M -15.61B -132M -114M -107M -97.65M -183M -12.51B -183M -1.27B -490M -6.4B -497M -486M -20.4B
Net Debt -474M -408M -384M -350M -655M -44.85B -657M -4.55B -1.76B -22.97B -1.78B -1.74B -73.15B -343M -295M -277M -253M -474M -32.44B -475M -3.29B -1.27B -16.61B -1.29B -1.26B -52.91B
Logo Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.
Employees
60
Date Price Change Volume
26-09-04 US$30.75 +2.77% 159,289
26-09-03 US$29.92 -1.51% 140,388
26-09-02 US$30.38 -2.69% 167,350
26-09-01 US$31.22 +4.28% 240,748
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.75USD
Average target price
77.56USD
Spread / Average Target
+152.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TECX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!